Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Annual Financial Report

28th Mar 2014 07:00

RNS Number : 3513D
Electrical Geodesics, Inc
28 March 2014
 



Electrical Geodesics, Inc.

 

Annual Report and Accounts for the year ended 31 December 2013

 

 

EUGENE, OREGON, USA, 28 March 2014- Electrical Geodesics, Inc. ("EGI" or the "Company"), a leading neurodiagnostic medical technology company, today announces that electronic copies of the Company's annual report and accounts for the year ended 31 December 2014 are available on the Company's website at www.egi.com.

 

 

-Ends-

 

 

EGI

UK: Christine Soden, CFO

+44 (0) 7710 484199

Peel Hunt LLP (NOMAD and Broker)

+44 (0) 20 7418 8900

James Steel, Clare Terlouw

FTI Consulting (PR Advisors)

+44 (0) 20 3727 1000

Simon Conway, Mo Noonan

 

 

Notes to Editors

 

Electrical Geodesics, Inc. in Summary

 

Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic products used to monitor and interpret brain activity based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company's technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.

 

EGI's dEEG systems, available in the GES 300 and now the GES 400 lines, capitalise on the Company's unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI's technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI's proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company's products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).

 

See our website www.egi.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSSEIFFWFLSEDD

Related Shares:

EGI.L
FTSE 100 Latest
Value9,157.12
Change14.39